Related Experiment Video

Updated: Jun 4, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Tyrosine Kinase Inhibitors: The Next Chapter in Reducing Treatment Burden for Exudative Retinal Diseases?

Pranesh Ravichandran1, Cecilia Canizela1, Abrahem Sayed2

  • 1College of Medicine, University of Illinois, Peoria, IL.

International Ophthalmology Clinics
|December 23, 2024
PubMed

Insights

Novel tyrosine kinase inhibitors (TKIs) offer a promising alternative to frequent anti-VEGF injections for retinal diseases. These new TKIs may reduce treatment burden and improve outcomes for conditions like AMD and DME.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Pharmacology

Background:

  • Dysregulated vascular endothelial growth factor receptor tyrosine kinases drive retinal diseases like age-related macular degeneration (AMD) and diabetic macular edema (DME).
  • These conditions are leading causes of vision loss with increasing global prevalence.
  • Current treatments involve frequent anti-vascular endothelial growth factor (anti-VEGF) injections, posing a significant patient burden.

Purpose of the Study:

  • To review novel tyrosine kinase inhibitors (TKIs) currently in development for exudative retinal diseases.
  • To explore how different TKI technologies and molecular targets may improve patient outcomes.
  • To highlight the potential of TKIs to reduce treatment frequency compared to standard care.

Main Methods:

  • Literature review of preclinical and clinical studies on TKIs for retinal diseases.
  • Analysis of TKI mechanisms targeting angiogenesis and exudation pathways.
  • Comparison of TKI therapeutic potential against current anti-VEGF therapies.

Main Results:

  • TKIs inhibit key signaling pathways involved in pathological angiogenesis and vascular leakage.
  • Emerging TKIs demonstrate potential for broader molecular targeting than current anti-VEGF agents.
  • Developmental TKIs aim to offer improved efficacy and reduced administration frequency.

Conclusions:

  • Novel TKIs represent a significant advancement in managing exudative retinal diseases.
  • Targeting multiple pathways with TKIs may lead to enhanced visual and anatomic outcomes.
  • TKIs hold promise for reducing the treatment burden associated with chronic retinal conditions.

More Related Videos

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.0K
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

21.1K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
140
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
391
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475